Login to Your Account

In The Clinic NEWS
New frontier in genomics

As far as gene editing technologies go, clustered regularly interspaced short palindromic repeats, or CRISPR, tends to suck up all the oxygen in the room.

But so far, clinical gene editing has been achieved by another method.

Nektar Therapeutics Inc.'s vice president of clinical development, Mary Tagliaferri, told BioWorld that the compelling objective response rate and impressive DCR with NKTR-214 when paired with Opdivo likely put the program in line for accelerated approval.

Otonomy Inc. CEO David Weber told BioWorld that researchers at his firm "have what we need to continue moving forward" in Ménière's disease with Otividex, the sustained-exposure formulation of dexamethasone that cheered investors by ringing the phase III bell after a similar late-stage experiment failed.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: